(ALT) Altimmune, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ALT) Altimmune, Inc. Complete Analysis Pack
Altimmune’s Business Model Canvas: Strategic Insights for Investors
Unlock the strategic blueprint behind Altimmune, Inc.’s business model. This Business Model Canvas breaks down how the company creates value, builds partnerships, and positions itself in a competitive biotech market. Ideal for investors, analysts, and strategists seeking clear, actionable insight. Get the full, ready-to-use version today.
Partnerships
Clinical trial sites and investigators
Altimmune uses external clinical trial sites and investigator networks to run human studies of pemvidutide and HepTcell, especially in Phase 1b and Phase 2. These partners handle patient recruitment, dosing, safety checks, and endpoint collection, which helps Altimmune scale trials without building a large in-house clinic network.
CROs and clinical operations vendors
Altimmune, Inc. relies on contract research organizations and clinical operations vendors to run trials, handle monitoring, biostatistics, data capture, and study logistics. That setup cuts internal headcount and helps move multi-site studies faster; in FY2025, Altimmune still reported no product revenue, so it kept R&D spend focused on outside trial execution.
CDMOs and manufacturing suppliers
Altimmune, Inc. depends on CDMOs and manufacturing suppliers for drug substance and drug product, since a clinical-stage biopharma has no internal commercial-scale plant; these partners handle process development, scale-up, fill-finish, and quality release. In 2025, aseptic fill-finish slots at top CDMOs were often booked 6 to 12 months ahead, so they are key to keeping trial material supplied without delays.
Regulatory agencies and ethics committees
FDA and local ethics boards set the trial rules for Altimmune, Inc.’s 2 lead programs, pemvidutide in obesity and MASH. Altimmune has to match protocol, safety reporting, and amendment plans to their feedback, because approvals and later-stage study timing depend on it.
- FDA shapes trial design
- IRBs review patient safety
- Protocol changes need alignment
- Critical for later-stage studies
Capital providers and public market investors
Altimmune, Inc. needs capital providers because it is still funding clinical R and D, and its 2025 10-Q showed cash, cash equivalents and investments of about $150 million, which supports the operating runway. Equity investors, underwriters and institutional holders matter here because public-market access is what keeps trial work moving, especially after Altimmune posted a 2024 net loss of roughly $101 million.
- Funds R and D before product sales
- Public markets extend cash runway
- Institutional holders support financing
Altimmune’s Trials Run on Partners, Not a Big In-House Engine
Altimmune, Inc. depends on CROs, clinical sites, CDMOs, and regulators to run pemvidutide and HepTcell trials, because it has no large in-house clinical or manufacturing base. In FY2025, cash, cash equivalents, and investments were about $150 million, so partner access helps stretch R&D spend.
| Partner | Role | FY2025 note |
|---|---|---|
| CROs and sites | Trial execution | Multi-site studies |
| CDMOs and FDA | Supply and oversight | No product revenue |
What is included in the product
Detailed Word Document
A concise Business Model Canvas of Altimmune, Inc. showing how its obesity and liver disease therapies create value for patients, providers, and investors.
Customizable Excel Spreadsheet
Clarifies Altimmune’s business model in one view, helping teams quickly spot gaps, risks, and priorities.
Reference Sources
Provides a credible source trail for Altimmune, Inc. that strengthens confidence and speeds decision-making.
Activities
Pemvidutide clinical development
Pemvidutide is Altimmune, Inc.'s lead investigational asset and the core focus of its clinical work. The company is running Phase 2 studies in obesity and liver disease, including NASH, with dose finding, safety, efficacy, and biomarker analysis driving the program.
HepTcell clinical development
HepTcell clinical development is Altimmune, Inc.’s Phase 2 path for chronic hepatitis B, centered on patient enrollment and immune-response readouts that test whether the T-cell immunotherapy can drive functional control of infection. It also broadens Altimmune, Inc.’s pipeline beyond metabolic disease, reducing single-therapy dependence.
Clinical trial design and execution
Altimmune designs protocols, endpoints, and inclusion criteria for each study, then runs site activation, data integrity checks, and adverse-event tracking. That matters because its 2025 pemvidutide program relied on proof-of-concept readouts from phase 2 studies in 212 MASH patients and 391 adults with obesity, where execution quality drives signal clarity and go/no-go decisions.
Regulatory and scientific strategy
Altimmune, Inc. uses regulatory and scientific strategy to turn its Phase 2 data into briefing books, safety updates, and development plans for regulators. It also presents data at scientific meetings and in publications, helping support future registrational pathways for pemvidutide across obesity and MASH.
- Builds FDA meeting packages
- Updates safety and efficacy data
- Uses publications to widen evidence
- Supports registrational trial planning
CMC and supply chain management
Altimmune, Inc. needs CMC readiness and tight supply chain control before larger trials can scale, because every batch must meet specs, be released on time, and stay consistent across sites. That means managing raw materials, vendor controls, and lot release so trial supply stays reliable and study delays stay low.
- Ready GMP batches before scale-up
- Control materials, vendors, release
- Cut delay and quality risk
Altimmune’s Phase 2 trials drive pemvidutide’s next big decision
Altimmune, Inc. focuses Key Activities on advancing pemvidutide and HepTcell through Phase 2 clinical work, with trial design, site execution, safety monitoring, and biomarker analysis driving go/no-go decisions. In 2025, pemvidutide data came from 212 MASH patients and 391 adults with obesity, so study quality directly shapes the next development step.
| Key activity | Latest data |
|---|---|
| Phase 2 execution | 212 MASH; 391 obesity |
What You See Is What You Get
Business Model Canvas
This preview shows the actual Altimmune, Inc. Business Model Canvas document you will receive after purchase. It is not a sample or mockup—what you see here is a direct excerpt from the final file. Once you buy, you’ll get the same professionally formatted document in full.
Resources
Pemvidutide asset
Pemvidutide is Altimmune, Inc.'s lead asset, a GLP-1 and glucagon dual receptor agonist that anchors its obesity and liver disease strategy. In recent clinical work, it has shown double-digit weight loss and meaningful liver-fat reduction signals, making it the core value driver in the Company Name's pipeline.
HepTcell asset
HepTcell is Altimmune, Inc.'s second major clinical program and a key resource that broadens the Company’s pipeline beyond obesity and liver disease. It is an immunotherapeutic for chronic hepatitis B, a market tied to about 254 million people worldwide living with chronic HBV, giving Altimmune a second therapeutic focus with high unmet need.
Clinical and preclinical data package
Altimmune’s clinical and preclinical data package is its core proof set: it combines safety, pharmacology, and efficacy readouts from its studies to support partnering, pipeline advancement, and FDA discussions. These data also anchor investor updates, especially as the company advances programs like pemvidutide through late-stage trials.
Scientific and development team
Altimmune's scientific and development team is the key resource behind its clinical pipeline, with in-house leadership guiding immunology and metabolic disease programs, vendor oversight, trial execution, and FDA strategy. In a small biotech, human capital drives value; Altimmune reported 61 employees in its latest filing.
- Clinical, immunology, metabolic expertise
- Coordinates trials and vendors
- Small-team human capital is core
Corporate headquarters and operating infrastructure
Altimmune is headquartered in Gaithersburg, Maryland, where its corporate base supports management, finance, legal, and development oversight. For a public clinical-stage biotech, this operating spine is essential: it helps run trials, manage compliance, and steer capital use across 2025/2026 milestones.
- Gaithersburg HQ
- Supports core functions
- Needed for public biotech
Altimmune’s Core Assets Power a Diversified Growth Story
Altimmune, Inc.’s key resources are its lead clinical assets, pemvidutide and HepTcell, plus the data set that supports both programs. Together, they anchor its obesity, liver disease, and chronic hepatitis B strategy, while reducing reliance on any single product.
| Key resource | Why it matters |
|---|---|
| Pemvidutide | Main value driver |
| HepTcell | Pipeline diversification |
Value Propositions
Dual receptor obesity candidate
Pemvidutide is Altimmune, Inc.'s dual GLP-1/glucagon agonist, designed to pair appetite control with higher energy use. In Phase 2 obesity data, the program has shown double-digit weight loss, which sets it apart from single-pathway candidates and supports both weight reduction and broader metabolic effects.
Liver disease development program
Altimmune’s liver disease program centers on pemvidutide for MASH/NASH, a market where no approved therapy has yet fixed the core problem of liver fat, inflammation, and fibrosis. By pairing this with its obesity franchise, the same GLP-1/ glucagon asset can target multiple metabolic indications, which could widen addressable patients beyond the roughly 100 million Americans with fatty liver disease.
Chronic hepatitis B immunotherapy
HepTcell is Altimmune, Inc.'s chronic hepatitis B immunotherapy designed to target persistent HBV infection and drive immune control, not just viral suppression. This matters in a market with about 254 million people living with chronic hepatitis B worldwide, where long-term disease control is still hard to achieve.
By aiming for a functional cure-type response, HepTcell offers a differentiated path versus standard antivirals, which often require lifelong use and do not clear infection.
Two-program pipeline diversification
Altimmune, Inc. spreads risk across 2 programs: a metabolic asset and an infectious-disease immunotherapy asset, so it is not tied to one indication. That setup lowers binary pipeline risk, because success or failure in one disease area should not fully drive Altimmune, Inc.'s value.
- 2-program pipeline
- Metabolic + infectious disease
- Lower binary risk
Clinical-stage optionality
Altimmune’s clinical-stage optionality comes from one asset, pemvidutide, with three possible value routes: obesity, MASH/NASH, and chronic hepatitis B. Early human data can still re-rate the story fast, because any clear win in one indication could support partnering or licensing before late-stage spend rises.
- One asset, three shots at value.
- Partnering can follow proof of concept.
- Early data drive most upside.
Altimmune’s 3-Way Shot at Obesity, Liver Disease, and HBV
Altimmune, Inc. offers one main clinical asset, pemvidutide, with 3 value paths: obesity, MASH/NASH, and chronic hepatitis B. Its dual GLP-1/glucagon design aims to deliver double-digit weight loss plus metabolic benefit, while HepTcell targets functional cure in a 254 million-person HBV market.
| Signal | Value |
|---|---|
| Programs | 2 |
| Indications | 3 |
| Fatty liver patients | 100M+ in the U.S. |
Customer Relationships
Site-based clinical engagement
Altimmune, Inc. keeps customer relationships tightly centered on investigators and trial sites, so each study needs hands-on support, fast answers, and clean protocol execution. As a clinical-stage Company with no commercial product sales, this site-by-site work is the core relationship model.
Scientific collaboration with physicians
Altimmune, Inc. builds scientific ties with obesity and liver disease specialists through trial readouts, congress talks, and advisory feedback. In a specialist-led market, this matters: Altimmune reported no product revenue in 2025 and stayed focused on R&D, so credibility with physicians is a key driver of adoption.
Investor relations communication
Altimmune uses quarterly earnings releases, SEC filings, and investor presentations to update shareholders on trial progress, cash use, and key milestones. The cadence is recurring and information-heavy, with the company also reporting through Form 10-Q and Form 10-K each fiscal year.
Regulatory consultation relationship
Altimmune, Inc. keeps a steady line with regulators during pemvidutide development, covering protocol alignment, safety reporting, and study amendments. That matters because its phase 2 MASH work has already generated enough clinical activity to require repeated FDA/IRB review, and each regulatory turn affects trial pace and design.
Ongoing regulator dialogue
Aligns protocols and safety reports
Can speed or slow development
Future patient and caregiver education
As Altimmune moves closer to commercialization, future patients will need clear dosing, titration, and treatment-goal guidance, while caregivers and clinicians need simple safety and efficacy updates. With 0 product revenue today, this relationship should matter more as the company shifts from trials to launch.
Teach dosing and goal setting early.
Share plain safety and efficacy data.
Support caregivers near launch.
Altimmune’s Growth Hinges on Clinical Credibility, Not Product Sales
Altimmune, Inc. keeps customer relationships centered on trial sites, regulators, and specialist physicians, with high-touch support for protocol execution and safety reporting. In 2025, it still had 0 product revenue, so adoption depends on clinical credibility, not sales force scale.
| Customer group | 2025 proof point |
|---|---|
| Investigators | Site-level trial support |
| Physicians | Conference and readout updates |
| Shareholders | Quarterly SEC updates |
Channels
Clinical trial sites
Clinical trial sites are Altimmune, Inc.’s core channel for reaching study participants, because they handle informed consent, dosing, safety monitoring, and data capture for every active program. In 2025, this channel stayed central as Altimmune advanced pemvidutide through late-stage obesity and MASH work, where site execution directly drives enrollment speed and data quality.
Investor communications
Altimmune, Inc. uses SEC filings and corporate presentations to reach capital markets with trial updates, cash position, and strategy. This channel supports financing and keeps shareholders current on progress, including program milestones and liquidity needs.
Scientific conferences and publications
Altimmune, Inc. uses medical meetings and peer-reviewed journals to share Phase 2 and Phase 3 data, including pemvidutide trial results, with clinicians, researchers, and partners. This channel matters for clinical-stage biopharma because credibility is built on hard data, not sales, and recent conference abstracts and journal papers can move partner interest fast.
Corporate website and media releases
Altimmune uses its corporate website and media releases to push pipeline news, data readouts, and milestone updates to investors and partners. It is a low-cost channel with broad reach, and one press release can hit thousands of readers at near-zero distribution cost.
- Pipeline updates
- Trial data releases
- Broad, low-cost reach
Business development outreach
Altimmune, Inc. uses direct outreach to pharma and biotech firms to push licensing, co-development, and strategic deals before commercialization. As a pre-commercial company with no product revenue in its latest filings, this channel is key for early value realization.
- Direct pharma/biotech outreach
- Supports licensing and co-development
- Creates pre-launch value
Altimmune’s 2025 Growth Channels: Trials, Filings, and Partner Talks
Altimmune, Inc.’s main channels in 2025 were trial sites for pemvidutide studies, SEC filings and investor materials, medical meetings and journals, and direct business development outreach. These channels matter because Altimmune is still pre-commercial, so data readouts, cash updates, and partner talks are the main way it reaches investors and potential licensors.
| Channel | Role |
|---|---|
| Trial sites | Enroll and monitor patients |
| SEC and IR | Update markets on 2025 progress |
| BD outreach | Support licensing talks |
Customer Segments
Adults with obesity
Adults with obesity are Altimmune, Inc.’s core future customer group for pemvidutide, a GLP-1/glucagon dual agonist in late-stage development. In the U.S., obesity affects about 42% of adults, or roughly 100 million people, and only a small share use effective long-term drug therapy, leaving a large chronic market for weight-loss treatment.
Patients with NASH
Patients with NASH are a core target for pemvidutide, because the disease combines metabolic liver inflammation with fibrosis risk and still has no approved drug therapy. NASH affects an estimated 3% to 5% of U.S. adults, and about 20% of patients can progress to cirrhosis, making it a high-unmet-need specialty market.
Adults with chronic hepatitis B
Adults with chronic hepatitis B are HepTcell’s core market: WHO estimates about 254 million people live with chronic HBV worldwide, and they need durable immune control plus long-term disease management. For Altimmune, Inc., this is the main immunotherapy segment, where even a small share of a large, chronic patient pool can drive meaningful value.
Hepatology and obesity specialists
Hepatology and obesity specialists are Altimmune, Inc.'s key gatekeepers: they enroll patients, shape trial readouts, and drive post-approval use. This matters in a market where obesity affects 40.3% of U.S. adults and MASH is often managed by liver specialists, so trust from these physicians can directly move adoption.
- Guide trial enrollment and endpoints
- Influence prescribing after approval
- Need strong safety and efficacy data
Altimmune, Inc. must win credibility with this small but high-impact group, since specialist opinion can speed uptake in both obesity and hepatology care pathways.
Pharma and biotech partners
Pharma and biotech partners are Altimmune, Inc.'s key pre-market buyers for licensing or co-development. With no approved product and a lead pipeline centered on pemvidutide, these partners can fund late-stage trials, add development know-how, and supply the sales network Altimmune does not yet have.
- License deals can bring cash before launch
- Partners de-risk Phase 2/3 execution
- Commercial reach matters before revenue starts
Altimmune Targets Massive, Unmet Markets in Obesity, HBV, and MASH
Altimmune, Inc. serves three main customer groups: adults with obesity and MASH for pemvidutide, adults with chronic hepatitis B for HepTcell, and the specialists and pharma partners who decide trial progress, prescribing, and deal terms. The biggest pools are large and chronic: about 100 million U.S. adults with obesity, 254 million people with chronic HBV worldwide, and no approved drug yet for NASH/MASH.
| Segment | Key data |
|---|---|
| Obesity | ~100M U.S. adults |
| Chronic HBV | 254M global patients |
| MASH/NASH | No approved drug |
Cost Structure
Clinical trial expenses
Clinical trial expenses are Altimmune, Inc.’s biggest cost bucket because human studies drive site fees, patient procedures, labs, imaging, and ongoing monitoring. Its Phase 2b IMPACT study in MASH enrolled 212 patients, and keeping both Phase 1b and Phase 2 programs moving means sustained R&D spending through each dosing and readout cycle.
Research and development payroll
Altimmune has to fund scientists, clinicians, and program managers, and that R&D payroll is a recurring operating cost. In 2024, the Company reported about $68.6 million of research and development expense, showing how much internal labor is tied to trial oversight, data review, and vendor coordination.
Manufacturing and CMC costs
Altimmune, Inc. outsources most drug supply work, so cost structure is driven by process development, GMP batch runs, and release testing; these costs step up fast as study size and assay complexity grow. For biologics and peptides, external manufacturing often stays one of the priciest CMC lines, especially when scale-up, stability, and lot-release failure risk add rework.
General and administrative costs
Altimmune’s general and administrative costs are the public-company overhead layer: legal, finance, HR, facilities, SEC reporting, audit, and board governance. For a clinical-stage biotech with no product revenue, these costs still stay material because the company must keep the listing, filings, and controls running.
Legal, finance, HR, facilities
SEC filings and governance
Fixed overhead persists without sales
Regulatory and quality compliance costs
Regulatory and quality compliance costs are a fixed part of Altimmune, Inc.’s drug pipeline work: clinical programs need quality systems, audits, pharmacovigilance (safety reporting), and regulatory advisers. In 2025, these spend lines stayed embedded in R&D and G&A, because every investigational drug must meet FDA and trial-site rules before it can advance.
Quality systems support trial integrity.
Safety reporting adds recurring staffing costs.
Regulatory consulting is mandatory, not optional.
Altimmune’s Cost Engine: R&D, Trials, and Public-Company Overhead
Altimmune, Inc. has a cost base built around clinical trials, R&D staff, outsourced manufacturing, and public-company overhead. In 2024, research and development expense was about $68.6 million, while the Phase 2b IMPACT study enrolled 212 patients, showing how trial scale and lab work drive spending.
| Cost driver | Latest data |
|---|---|
| R&D expense | $68.6 million |
| IMPACT trial size | 212 patients |
Revenue Streams
No approved product sales
Altimmune, Inc. had no approved product sales in its latest reported period, so revenue from marketed drugs was $0. As a clinical-stage company, its economics are still driven by financing research and development, not selling products, which is the baseline revenue state until approval.
Equity financings
Altimmune, Inc. uses equity financings to raise operating cash, which is standard for precommercial biotech firms before product sales start. Public share offerings help pay for clinical trials, manufacturing scale-up, and corporate overhead; as of 2025, the company still relied on outside capital rather than product revenue.
At the market share sales
Altimmune, Inc. can use an at-the-market (ATM) program to sell new shares into the public market in small tranches, giving it flexible cash access when funding needs hit. That matters for a small-cap biopharma issuer because it can raise capital without a single large offering, but it also adds dilution for existing holders.
Licensing and collaboration upfronts
Altimmune, Inc. can use licensing and collaboration upfronts to collect cash when it grants development or regional rights to a larger pharma partner, which helps fund R&D before any product sale. This matters because its pipeline is still pre-commercial, so upfronts can support trials without waiting for launch revenue.
- Upfront cash lowers near-term funding pressure
- Rights deals can come from big pharma partners
- Supports development before commercialization
Milestones and future royalties
Altimmune, Inc. has no meaningful royalty stream today, so this line is still a future option, not a current cash driver. For a development-stage biotech, any milestone payment would be non-dilutive cash, while sales-based royalties would only show up after a partner advances a program through clinical and regulatory success.
- Milestones: non-dilutive cash
- Royalties: only after launch
- Value depends on partner execution
- Clinical success is the gatekeeper
Altimmune’s Cash Still Comes From Financing, Not Sales
Altimmune, Inc. had no approved-product sales in its latest reported period, so revenue was $0. Its cash inflow came from equity financing, including ATM share sales, plus any future upfronts or milestones from licensing deals. Royalty income is still a future item, not a current stream.
| Stream | Latest |
|---|---|
| Product sales | $0 |
| Equity financing | Primary cash source |
| Licensing | Potential future upfronts |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.